Last updated: 2026-09-16 09:04:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Stevanato Group S.p.A. (STVN) operates in the -- sector and is listed on NYSE. The stock is currently priced at $21.50, with a market capitalisation of $5.82B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $12.89 to $28.00. This page covers its latest market performance, valuation, price trends and company information.
$5.82B | |
$21.15 | |
$36.30 | |
$12.89 | |
$21.32 | |
258.42K | |
378.11K | |
-- | |
$28.00 | |
$12.89 | |
-- | |
-- |
Stevanato Group S.p.A. (STVN) is trading at $20.75 in pre-market trading as of 2026-09-15 23:31:00, down 2.67% ($0.57) from the previous close of $21.32
Pre-market trading shows how investors are pricing STVN before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Stevanato Group S.p.A. (STVN) moved from $20.51 to $21.50, representing a gain of 4.80% ($0.98).
The stock traded between $19.74 and $21.87 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 338.01 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 56.9%
STVN is currently trading at $21.50, placing it 56.9% of the way from its 52-week low of $12.89 to its 52-week high of $28.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America.
| Employees | 5795 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Stevanato Group S.p.A. (STVN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.